Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Current Treatment of 1L Hodgkin Lymphoma

University of Miami Sylvester Comprehensive Cancer Center

C. Moskowitz

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

ASCO® 2024 Summary: "Treatment of Relapsed HL - Updated Options in L…

2024 ASCO® Annual Meeting Insights Hub

P. Johnson

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Unveiling the Facets of Post-Sepsis Syndrome: Physical and Neuropsyc…

Houston Methodist

D. Moran

Treatment Updates and Management of Hodgkin Lymphoma

Integrity CE

A. Niu, D. Wallace, M. Cortese

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

Emerging and Current Treatment for Hodgkin Lymphoma in 2024

Indy Hematology Review

S. Ansell

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Mana…

2024 ASCO® Annual Meeting Insights Hub

M. Minnema

Summary of Recent Updates in Advanced Hodgkin Lymphoma

SOHO Brazil 2024

C. Moskowitz

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

UChicago Medicine Best of ASCO® 2024: HL, DLBCL, MCL

UChicago Medicine Annual Practice Updates in Hematology and Oncology

A. Rojek

Key Lymphoma Updates From ASH

Memorial Sloan Kettering Cancer Center

P. Torka

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith

EHA 2024 Insights: Treatment of Advanced Stage, High-Risk Hodgkin's …

Insights from 2024 EHA Annual Meeting

M. Salamoon